17-hydroxyprogesterone ester-containing oral compositions and related methods
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
1. An oral pharmaceutical composition comprising or prepared from:
a therapeutically effective amount of particulate form 17HPC, and a pharmaceutically acceptable carrier, said therapeutically effective amount of 17HPC ranging from 150 mg to 750 mg and having a D90 particle diameter of no more than about 200 nm, wherein administration of said composition to a subject results in at least one of a bioavailability ratio of greater than 2.0 when comparing an 800 mg BID dose to a 400 mg BID dose, and a C avg in said subject of greater than 6.4 ng/mL.
2. The oral pharmaceutical composition of claim 1 , wherein the composition releases greater than 10% after 1 hour when tested using a USP Type II apparatus at 50 rpm in an aqueous media having 1.5× or greater sink condition at 37.0° C. (±0.5).
3. The oral pharmaceutical composition of claim 1 , wherein the composition releases greater than 10% after 1 hour when tested using a USP Type II apparatus at 50 rpm in an aqueous media having 3× or greater sink condition at 37.0° C. (+0.5).
4. The oral pharmaceutical composition of claim 1 , wherein the composition has at least 225 mg of 17HPC.
5. The oral pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier comprises one or more of a diluent, binder, disintegrant, lubricant or surfactant.
6. The oral pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier comprises a lipophilic or hydrophilic additive.
7. The oral pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier comprises a lipophilic or hydrophilic surfactant.
8. The oral pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier comprises a lipophilic surfactant and a hydrophilic surfactant.
9. The oral pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier comprises a non-ionic or ionic surfactant.
10. The oral pharmaceutical composition of claim 1 , wherein said 17HPC comprises at least one form of fully solubilized, partially solubilized, crystalline particulate, amorphous particulate, and a combination thereof.
11. The oral pharmaceutical composition of claim 1 , wherein said particulate form of 17HPC has a mean particle diameter of less than about 60 nm.
12. The oral pharmaceutical composition of claim 1 , wherein the composition has a crystallization inhibitor or a particle agglomeration inhibitor.
13. The oral pharmaceutical composition of claim 1 , wherein the composition is a powder, granulate, particulate, bead, pellet, sprinkle, suspension, solution, tablet, caplet, capsule, or a combination thereof.
14. The oral pharmaceutical composition of claim 1 , wherein the composition is controlled release or immediate release.
15. The oral pharmaceutical composition of claim 1 , wherein the composition is a coated or uncoated tablet or caplet.
16. The oral pharmaceutical composition of claim 1 , wherein the composition is a monolithic or multilayered tablet.
17. The oral pharmaceutical composition of claim 1 , which when administered once, twice or three times a day as one to twelve unit dosage forms total per day to a human subject, provides a 17HPC C avg-24h of greater than at least one of 0.1, 0.5 and 1.0 ng/mL.
18. A method of treatment comprising administering to a subject an oral pharmaceutical composition comprising or prepared from:
a therapeutically effective amount of particulate form 17HPC comprising from 150 mg to 750 mg of 17HPC having a D90 particle diameter of no more than about 200 nm, a pharmaceutically acceptable carrier, and one or more additional agents chosen from pharmaceutical agents, vitamins, minerals, supplements, wherein said administration results in at least one of a bioavailability ratio of greater than 2.0 when comparing an 800 mg BID dose to a 400 mg BID dose, and a C avg in said subject of greater than 6.4 ng/mL.
19. The method of claim 18 , wherein said method comprises administering said pharmaceutical composition once, twice or three times a day as one to twelve unit dosage forms total per day to a human subject, resulting in a 17HPC C avg-24h of greater than at least one of 0.1, 0.5 and 1.0 ng/mL in said human subject.
20. The method of claim 19 , wherein said particulate form of 17HPC has a mean particle diameter of less than about 60 nm.